Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
Skye Bioscience, Inc. (SKYE)
Company Research
Source: GlobeNewswire
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with a focus on obesity and ocular indications, is pleased to announce the appointment of Dr. Annalisa Jenkins, MBBS, FRCP, to the Company’s Board of Directors. Dr. Jenkins’ esteemed career spans more than 25 years in the global pharmaceutical, biotechnology and life science industry. She has broad experience in building and leading teams and developing strategies that have resulted in the advancement of new products across multiple disease areas from discovery through to clinical development, regulatory approval and commercialization worldwide. Dr. Jenkins currently provides board level and consulting services to organizations across the life science and healthcare industry. She previously se
Show less
Read more
Impact Snapshot
Event Time:
SKYE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SKYE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SKYE alerts
High impacting Skye Bioscience, Inc. news events
Weekly update
A roundup of the hottest topics
SKYE
News
- Skye Bioscience to Present at Upcoming Investment ConferencesGlobeNewswire
- Skye Bioscience, Inc. (NASDAQ: SKYE) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $25.00 price target on the stock.MarketBeat
- Skye Bioscience, Inc. (OTCMKTS: SKYE) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $25.00 price target on the stock.MarketBeat
- Skye Bioscience Uplists to The Nasdaq Global MarketGlobeNewswire
- Skye Bioscience, Inc. (OTCMKTS: SKYE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $20.00 price target on the stock, up previously from $12.00.MarketBeat
SKYE
Sec Filings
- 4/24/24 - Form POS
- 4/11/24 - Form EFFECT
- 4/10/24 - Form 424B3
- SKYE's page on the SEC website